Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: systematic review and meta-analysis by de la Iglesia-Garcia, Daniel et al.
ORIGINAL ARTICLE
Efﬁcacy of pancreatic enzyme replacement therapy
in chronic pancreatitis: systematic review
and meta-analysis
Daniel de la Iglesia-García,1,2 Wei Huang,1,3 Peter Szatmary,1 Iria Baston-Rey,2
Jaime Gonzalez-Lopez,4 Guillermo Prada-Ramallal,5 Rajarshi Mukherjee,1
Quentin M Nunes,1 J Enrique Domínguez-Muñoz,2 Robert Sutton,1 NIHR Pancreas
Biomedical Research Unit Patient Advisory Group1
ABSTRACT
Objective The beneﬁts of pancreatic enzyme
replacement therapy (PERT) in chronic pancreatitis (CP)
are inadequately deﬁned. We have undertaken a
systematic review and meta-analysis of randomised
controlled trials of PERT to determine the efﬁcacy of
PERT in exocrine pancreatic insufﬁciency (EPI) from CP.
Design Major databases were searched from 1966 to
2015 inclusive. The primary outcome was coefﬁcient of
fat absorption (CFA). Effects of PERT versus baseline and
versus placebo, and of different doses, formulations and
schedules were determined.
Results A total of 17 studies (511 patients with CP)
were included and assessed qualitatively (Jadad score).
Quantitative data were synthesised from 14 studies.
PERT improved CFA compared with baseline (83.7±6.0
vs 63.1±15.0, p<0.00001; I2=89%) and placebo (83.2
±5.5 vs 67.4±7.0, p=0.0001; I2=86%). PERT improved
coefﬁcient of nitrogen absorption, reduced faecal fat
excretion, faecal nitrogen excretion, faecal weight and
abdominal pain, without signiﬁcant adverse events.
Follow-up studies demonstrated that PERT increased
serum nutritional parameters, improved GI symptoms
and quality of life without signiﬁcant adverse events.
High-dose or enteric-coated enzymes showed a trend to
greater effectiveness than low-dose or non-coated
comparisons, respectively. Subgroup, sensitive and meta-
regression analyses revealed that sample size, CP
diagnostic criteria, study design and enzyme dose
contributed to heterogeneity; data on health inequalities
were lacking.
Conclusions PERT is indicated to correct EPI and
malnutrition in CP and may be improved by higher
doses, enteric coating, administration during food and
acid suppression. Further studies are required to
determine optimal regimens, the impact of health
inequalities and long-term effects on nutrition.
INTRODUCTION
Chronic pancreatitis (CP) is a progressive
ﬁbro-inﬂammatory disorder with sustained destruc-
tion of acinar, ductal and islet cells.1 CP has an
annual incidence of 4–12 per 100 000,2 increasing
worldwide.3 Aetiologies include environmental
toxins (prolonged, heavy alcohol exposure and cig-
arette smoking), hyperlipidaemia, single and/or
multiple genetic mutations (PRSS1, SPINK1, CTRC,
CASR, CFTR, CLDN2 and CPA1) and autoimmune
disease.3 4 CP is generally progressive, with marked
variation in abdominal pain and GI symptoms.
These greatly impair quality of life (QoL),5 while
exocrine pancreatic insufﬁciency (EPI) and diabetes
mellitus (DM) contribute to the low median
Signiﬁcance of this study
What is already known on this subject?
▸ Chronic pancreatitis (CP) is a major health
problem associated with health inequalities,
causing intractable abdominal pain,
peripancreatic complications, exocrine
pancreatic insufﬁciency (EPI), long-term
malnutrition and type 3c diabetes mellitus.
▸ Pancreatic enzyme replacement therapy (PERT)
is administered by some for EPI in CP but the
beneﬁts remain to be conﬁrmed.
▸ No meta-analysis has been conducted
previously of randomised clinical trials
assessing PERT for EPI in CP, while a previous
Cochrane review of PERT in CP was
inconclusive.
What are the new ﬁndings?
▸ This meta-analysis shows that PERT improves
the coefﬁcients of fat and nitrogen absorption
versus baseline and versus placebo, reducing
faecal fat excretion, faecal nitrogen excretion,
faecal weight and abdominal pain without
signiﬁcant adverse events. Follow-up studies
have found that PERT increases serum
nutritional parameters, improves GI symptoms
and quality of life without signiﬁcant adverse
events.
▸ Although there was signiﬁcant heterogeneity
between trials, subgroup analyses did not alter
the ﬁndings, and exclusion of trials with small
sample sizes (<40) or without imaging and/or
histology to establish CP signiﬁcantly reduced
the heterogeneity. Data on health inequalities
were sparse but for those on CP aetiology
attributed to alcohol excess.
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survival of 15–20 years from diagnosis.3 6 The prevalence of CP
has been estimated at circa 50 per 100 000 but this is a signiﬁ-
cant underestimate in view of incidence and median survival,
which suggests 100–200 per 100 000;3 similarly, EPI is probably
underestimated.3 Not surprisingly the management of CP and
its complications is resource intensive;7 were the management
of EPI and DM from CP to be improved and complications
reduced, these resources would be better spent.
EPI, characterised by inadequate pancreatic secretion of digest-
ive enzymes and bicarbonate, is one of the most signiﬁcant
complications of CP affecting >50% of diagnosed patients,8
resulting in compromised digestion, absorption and metabolism
of nutrients. Severe EPI tends to develop between 5 and 10 years
following an initial diagnosis of CP1 and can complicate acute
necrotising pancreatitis, cystic ﬁbrosis, DM, pancreatic cancer
and following surgery to bypass or resect the duodenum and/or
pancreas.9 EPI from CP reduces absorption of fat including
essential fatty acids, fat-soluble vitamins A, D, E and K, calcium,
magnesium, zinc, thiamine and folic acid.10 EPI from CP is fre-
quently experienced as diarrhoea, abdominal discomfort and/or
pain, weight loss and grossly as steatorrhoea (strictly, >7 g fat in
stool/24 hours).1 Intermediate and long-term malnutrition from
EPI increases the incidence of osteopenia/osteoporosis,11 low-
trauma fractures,12 cardiovascular diseases13 and infections.6
These complications develop on a background of health inequal-
ities, differences between people’s health as a result of social,
geographical or other factors, which are associated with less
favourable outcomes from CP; foremost is malnutrition.14 Rates
of alcoholism and smoking also have signiﬁcant socioeconomic
gradients, as do osteopenia/osteoporosis, DM and cardiovascular
diseases, making health inequality an independent risk factor for
the initiation and progression of CP.4
Pancreatic lipase is the principal enzyme in fat digestion
accounting for 90% of total lipase activity.9 Typically steator-
rhoea is unlikely until pancreatic lipase output falls to <10% of
normal,15 although subclinical EPI exists in many individuals
with CP.16 Large-scale Northern European studies suggest that
the majority of patients with EPI secondary to CP17 or pancre-
atic surgery18 are undertreated, likely because of insufﬁcient use
of pancreatic enzyme replacement therapy (PERT), suboptimal
scheduling in relation to meals or insufﬁcient control of gastric
acid output. The European Society for Parenteral and Enteral
Nutrition 2006 Guidelines19 suggest improvement of steator-
rhoea and maintenance of bodyweight as primary markers of
treatment success. Such end points, however, do not detect
subtler signs of malnutrition; nor do these guidelines suggest
formal measures to assess improvement of steatorrhoea.
Furthermore, these end points are unsuitable as primary
outcome measures for studies of PERT for EPI, particularly
short-term studies. For these, accurate measures that detect
alterations and/or improvements in absorption are neces-
sary.1 3 9 16 In practice, licensed enzyme replacement therapies
differ greatly: granules, tablets, microspheres, minimicrospheres
or capsules with enteric coating make comparisons challenging.
While the European Medicines Agency has delegated regulation
of PERT to national authorities, the US Food and Drug
Administration (FDA) addressed these differences in 2004
(updated in 2006),20 issuing requirements for new drug applica-
tions, specifying amount, stability and efﬁcacy. To date, six
enzymes have FDA approval: Creon, Pancreaze, Pertzye, Ultrase,
Viokase and Zenpep, all of porcine origin.
Questions remain as to the indications for and efﬁcacy of
PERT, including methods of assessment, formulation, dose,
administration and use of acid suppression. Shaﬁq et al21 con-
ducted a meta-analysis of PERT for CP regardless of the pres-
ence or absence of EPI. Data for weight loss and faecal fat were
combined from only two studies; the authors inferred that the
evidence for any beneﬁcial role of PERT in CP was inconclusive.
Waljee et al22 and Taylor et al23 combined trials in cystic ﬁbrosis
and CP, concluding that PERT improves but does not normalise
the coefﬁcient of fat absorption (CFA) in EPI; these two system-
atic reviews included a total of only three placebo-controlled
trials of PERT in CP, and no quantitative data were combined to
determine outcomes. Three further placebo-controlled trials of
PERT in CP have since been conducted, two of which were fol-
lowed by open-label extensions. We have therefore conducted a
systematic review of 17 randomised controlled trials (RCTs)
with meta-analysis of 14 to determine whether PERT is indi-
cated for EPI in CP, the impact of this treatment and factors
contributing to optimisation of PERT. Our study is strengthened
by meta-analysis of PERT versus baseline, PERT versus placebo
and PERT versus PERT to provide a more rigorous evaluation,
comparing CFA, coefﬁcient of nitrogen absorption (CNA),
faecal fat excretion (FFE), faecal nitrogen excretion (FNE),
faecal weight, abdominal pain and GI symptoms, bodyweight,
QoL and adverse events.
METHODS
Search strategy
All studies of PERT for EPI from CP were sought in Medline
(PubMed), Embase, Scopus, Science Citation Index Expanded
and the Cochrane Central Register of Controlled Trials between
January 1966 (the ﬁrst PERT study) and December 2015. The
following search terms were used in all possible combinations:
Chronic adj3 pancreatitis, exocrine pancreatic insufﬁciency,
pancrea$ insufﬁcien$; Randomized (or randomised) controlled
trial.pt., controlled clinical trial. pt, randomized.ab.placebo.ab.
drug therapy.fs, randomly.ab.trial.ab.group.ab; Enzymes.tw,
(enzyme$ adj1 (pancrea$ or replace$ or supplement$)).tw.(pan-
creatin or pancrease or pancrealipase or ultrase or cotazym or
creon or kreon or theraclec or encron or protilase or lipase or
hydrolase or exolipase or trigly-creidase or ALTU-135).tw;
English.lg. A manual reference search of reviews and conference
abstracts (2006–2015) was also undertaken.
Studies meeting all the following criteria were included: (1) in
English peer-reviewed journals; (2) prospective, randomised
design, investigating efﬁcacy and safety of PERT in EPI from CP
in adults (age ≥18 years; including patients who had pancreatic
resection for CP but not other indications); (3) reporting clinical
outcomes of interest; and (4) only the most recent study of mul-
tiple overlapping patient populations from the same institution
Signiﬁcance of this study
How might it impact on clinical practice in the
foreseeable future?
▸ This systematic review and meta-analysis of 17 randomised
trials of PERT for EPI in CP demonstrates the efﬁcacy of PERT
for correcting malnutrition in CP. PERT may be optimised by
higher doses, enteric coating, ingestion during food and acid
suppression.
▸ Further studies are needed to determine optimal methods
to address the impact of health inequalities on PERT for EPI
in CP.
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unless a prior study had higher quality. Abstracts, case reports,
letters, expert opinions, editorials, reviews and non-RCTs were
excluded.
Preferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) criteria24 were followed. Two authors
(DdlI-G and WH) independently scrutinised all identiﬁed
studies and reached consensus for ﬁnal inclusion, with adjudica-
tion (PS) when there was disagreement.
Data extraction
Two authors (DdlI-G and WH) extracted data independently
using predeﬁned standardised forms. These captured study
design, quality assessment (below), baseline characteristics,
health equality indicators (ethnicity, place of residence, socio-
economic background, employment/insurance status, profession,
alcohol use and cigarette smoking), diagnostic criteria for CP
and EPI, exclusion criteria, trial process, details of PERT and
outcomes of interest.
Outcomes of interest
CFA has been used most commonly as the primary end point to
assess the efﬁcacy of PERT on EPI due to CP and cystic ﬁbrosis
in RCTs, more informative than the presence or absence of stea-
torrhoea.22 23 We have therefore used CFA as the primary
outcome measure, calculated from fat intake (∼100 g/day of
dietary fat) and excretion (from 72 hours faecal collection)
using the following equation:
CFAð%Þ ¼ ½ð fat intake in g–– fat excretion in gÞ= fat intake in g
 100
CNA has been used to measure the effect of PERT on protein
absorption in EPI, ignored in previous systematic reviews;21–23
CNAwas calculated as follows:
CNAð%Þ ¼ ½ðnitrogen intake in g––nitrogen excretion in gÞ
=nitrogen intake in g  100
Secondary outcomes included CNA, FFE, FNE, faecal weight,
faecal consistency (formed/normal or soft/watery), faecal fre-
quency (stools per day), ﬂatulence (none/mild/moderate/severe),
abdominal pain (none/mild/moderate/severe) and adverse events.
When available, serum nutritional markers, diarrhoea, weight
loss/gain and QoL were included.
Quality assessment
Two authors (DdlI-G, WH) scored each included study using
the Jadad system25 that assesses randomisation (0 or 1), double-
blinding (0, 1 or 2), recording of dropouts and/or withdrawals
(0 or 1) and allocation concealment (0 or 1), with a score ≥3
indicative of high quality.
Statistical analysis
Means and SDs of continuous variable were used for
meta-analysis, estimated26 when medians were given. If CFA
and CNA were not available, these were calculated as described.
If different protocols of PERT were used in any single study,
average daily lipase dose was calculated in United States
Pharmacopoeia (USP) units. Meta-analyses compared PERT
versus baseline, PERT versus placebo or PERT versus PERT.
Forest plots were generated using Review Manager V.5.3 soft-
ware (Cochrane Collaboration, Oxford, UK). Continuous vari-
ables were expressed as weighted mean differences (WMD) and
categorical variables as ORs with 95% CIs. A random-effects
model27 was employed to ensure conservative estimates in
meta-analyses. Heterogeneity was evaluated using χ2 with
p<0.1 considered signiﬁcant. Statistical heterogeneity was
assessed using I2 values with cut-offs of 25%, 50% and 75% to
indicate low, moderate and high heterogeneity, respectively.28
Subgroup analyses examined studies of high quality; parallel,
multicentre design; samples ≥40 and Western populations.
Sensitivity analyses were conducted by diagnostic criteria and
inclusion of pancreatic surgery.
Meta-regression analyses assessed inﬂuence of age, gender,
study design, study quality, lipase dose and publication year on
summary estimates using Stata SE V.13 Software (StataCorp,
Texas, USA); p<0.05 was considered signiﬁcant. Publication
bias was assessed using funnel plots,29 and p values generated
from both CFA and FFE as per Begg and Mazumdar30 and
Egger et al;31 p<0.10 was considered signiﬁcant.
Patient and public involvement
The research design, methods, results and their interpretation
were reviewed by the NIHR Liverpool Pancreas Biomedical
Research Unit Patient Advisory Group, and modiﬁcations made
accordingly. The group is comprised of patients with a history
of acute pancreatitis, CP or pancreatic cancer, or their carers, or
interested members of the public.
RESULTS
Design and quality assessment of included studies
The PRISMA ﬂow diagram is shown in ﬁgure 1; 17 studies32–48
were included. Study design and quality assessment are shown in
table 1. There were four32 33 40 45 conducted in the USA,
nine34–39 41 43 44 in Europe, two46 47 in the USA and Europe,
one42 in South Africa and one48 in India. Twelve32–37 39–41
43 44 47 had cross-over designs (two41 47 multicentre);
ﬁve38 42 45 46 48 had parallel designs (three45 46 48 multicentre).
Five41 43 46–48 reported sample size calculations, four41 46–48
using change of CFAvalues and one43 cumulative 13CO2 recovery
rate. Detailed Jadad scoring is shown in online supplementary
Figure 1 Preferred Reporting Items for Systematic Reviews and
Meta-analyses ﬂow chart of study selection process. CP, chronic
pancreatitis.
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table S1. All seven high-quality studies35 38 41 45–48 were
double-blinded.
Baseline parameters of patients with CP
These are shown in online supplementary table S2; 511 patients
with CP were enrolled and 477 analysed; median age was
50 years. Gender was reported in most studies (pooled 76.4%
males). Ethnicity was reported in only four.45–48 None reported
residence data, smoking, socioeconomic status or profession.
Five41 42 46–48 reported body mass index. Nine32 33 35
36 39 40 42 44 48 included data on coexisting DM (pooled fre-
quency 49.5%). Patients in seven studies32 35 37 40–42 45 did not
have pancreatic surgery recorded, while the remaining studies
included such patients. Ten studies32–36 38–40 42 44 reported aeti-
ology, with alcohol excess pooled at 89.1%.
Inclusion and exclusion criteria
The diagnostic criteria for CP and EPI are shown in table 2. CP
was diagnosed by imaging and/or histology in six
studies,33 36 39 46–48 imaging and/or history in seven35 37 38 41–44
and history, abnormal secretin-pancreatozymin test and/or hist-
ology in one.34 The diagnostic criteria in the remaining three
studies32 40 45 were unclear. EPI was deﬁned by FFE >7–8 g/day
in ﬁve,33 35 36 41 43 by FFE >10–15 g/day and/or CFA ≤80% in
nine and by faecal elastase ≤100 mg/g in one study.47 One
study32 did not report criteria for EPI and 140 included CP
patients with documented symptomatic steatorrhoea.
Ten36 38 39 41–43 45–48 reported detailed exclusion criteria.
Details of trial process
The trial process and adverse events are shown in table 2. RCTs
of PERT typically had a run-in phase to scrutinise and stabilise
eligible participants before treatment initiation. During run-in
or washout, PERTwas stopped. Six studies34–37 43 44 reported a
3–15-day no-treatment run-in, while ﬁve38 40 45–47 had a
5–14-day period for placebo administration before commencing
the trial. Three studies41 42 48 reported a 14-day run-in with the
last seven days before randomisation treated by PERT. The
remaining three studies32 33 39 did not report a run-in phase.
During treatment, PERT or placebo was used with or without a
washout in between switching treatments. Daily fat intake was
recorded in the majority (normally 100 g/day), but not in
three.36 37 44 Only three37 46 47 reported use of a faecal dye.
The equilibration time was normally 2–5 days before a 3-day
period of faecal fat collection. Adverse events were reported in
six,36 41 45–48 with an incidence of 11.4–42.7%.
RCT study duration ranged from several days to 2 months;
none assessed long-term effects of PERT, although two open-
label extension studies examined the nutritional impact of PERT
over 6 months49 and 12 months.50
Composition and administration schedule of PERT
Details of PERT composition and administration schedules are
shown in online supplementary table S3. Converted pancreatic
lipase doses in USP units are shown in ﬁgure 2. The source of
pancreatic enzymes and conversion factors is shown in online
supplementary table S4. PERT formulations were granules,
microtablets, microspheres and minimicrospheres with or
without enteric coating. Four studies32–34 36 included non-
coated and enteric-coated enzymes. Two studies46 47 used
delayed release enteric-coated minimicrospheres (Creon 12000)
or microspheres (Zenpep).
Delhaye’s study39 found no signiﬁcant differences in the efﬁ-
cacy of Pancrease HL and Creon 3 (both enteric-coated micro-
spheres). Halm’s study41 showed the primary outcome CFA and
adverse events to be similar for Creon 10000 microspheres and
minimicrospheres. Vecht’s study44 found low-dose (lipase
10 000 USP units tds) improved fat absorption and reduced
symptoms compared with normal dose (lipase 20 000 USP units
tds) Pancrease when combined with strong acid inhibition (ome-
prazole 60 mg). Toskes’s study47 showed low-dose (lipase
7×5000 USP units/day) and high-dose (lipase 7×20 000 USP
Table 1 Design and quality assessment of included studies
Study Year Country Study period Design
Single or
multicentre Type*
No. of
groups
Sample size
calculation
Blinding
method
Jadad
score
Graham32 1979 USA NR Cross-over Single PERT vs PERT 5 No NR 1
Dutta et al33 1983 USA NR Cross-over Single PERT vs PERT 3 No NR 1
Lankisch et al34 1986 Germany NR Cross-over Single PERT vs PERT 3 No NR 1
Halgreen et al35 1986 Denmark NR Cross-over Single PERT vs placebo 2 No Double 3
Gouerou et al36 1989 France NR Cross-over Single PERT vs PERT 2 No NR 2
Jørgensen et al37 1991 Denmark NR Cross-over Single PERT vs PERT 3 No NR 1
Paris38 1993 France June 1986 to June 1987 Parallel Single PERT vs placebo 2 No Double 3
Delhaye et al39 1996 Belgium March 1993 to May 1994 Cross-over Single PERT vs PERT 4 No NR 2
Opekun Jr et al40 1997 USA NR Cross-over Single PERT vs PERT vs
placebo
4 No Single 1
Halm et al41 1999 Germany NR Cross-over Multicentre PERT vs PERT 2 Yes Double 4
O’Keefe et al42 2001 South
Africa
NR Parallel Single PERT vs placebo 2 No NR 2
Domínguez-Muñoz
et al43
2005 Spain NR Cross-over Single PERT vs PERT 3 Yes Not
possible
2
Vecht et al44 2006 Netherlands NR Cross-over Single PERT vs PERT 2 No Double 2
Safdi et al45 2006 USA NR Parallel Multicentre PERT vs placebo 2 No Double 3
Whitcomb et al46 2010 USA/Europe April 2007 to August 2008 Parallel Multicentre PERT vs placebo 2 Yes Double 5
Toskes et al47 2011 USA/Europe January 2008 to March 2009 Cross-over Multicentre PERT vs PERT 2 Yes Double 3
Thorat et al48 2012 India June 2008 to May 2010 Parallel Multicentre PERT vs placebo 2 Yes Double 5
*Refers to comparisons of different types of PERT, different doses of the same PERT.
NR, not reported; PERT, pancreatic enzyme replacement therapy.
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units/day) Zenpep without acid inhibition both signiﬁcantly
improved CFA, CNA, bodyweight and body mass index.
Subgroup analysis, however, revealed that a higher dose of
PERT may be needed for more severe EPI.
Domínguez-Muñoz’s study43 suggested that PERT administra-
tion during or after meals may be more appropriate than before
meals. In all other studies, PERTwas taken before or with meals
or snacks at various different doses. The use of proton pump or
H2 inhibitors was reported or allowed in ﬁve
34 39 44 46 48 with
only one39 comparing PERTwith versus PERTwithout omepra-
zole; in this last study, omeprazole improved fat digestion but
compromised protein digestion.
Meta-analysis results
In total, 14 of 17 included RCTs32–38 40 42 44–48 had data on
predeﬁned clinical outcomes of interest suitable for quantitative
comparison of PERT versus baseline, versus placebo and versus
PERT.
PERT versus baseline
The clinical outcomes of PERT versus baseline are presented in
ﬁgure 3 and summarised in table 3. Eleven studies32–34
38 40 42 44–48 reported CFA; pooled results demonstrated that
PERT increased CFA versus baseline (83.7±6.0 vs 63.1±15.0;
WMD: 2.28, 1.50 to 3.06; p<0.00001) with high heterogen-
eity (I2=89%). Four studies42 46–48 reported CNA; PERT also
improved CNA versus baseline (WMD: 1.01, 0.39 to 1.62;
p=0.001).
Thirteen papers32–34 36–38 40 42 44–48 reported FFE, which
with FNE32 38 46 48 and faecal weight32 34 38 42 44 48 were sig-
niﬁcantly reduced by PERT (all p≤0.001). PERT improved
symptoms of ﬂatulence, abdominal pain and faecal consist-
ency,46 48 without signiﬁcant effects on stool frequency.37 48
PERT versus placebo
The clinical outcomes of PERT versus placebo are displayed in
ﬁgure 4 and summarised in table 3. Pooled results from seven
studies35 38 40 42 45 46 48 found that PERT greatly increased
CFA over placebo (83.2±5.5 vs 67.4±7.0; WMD: 1.67, 0.81
to 2.53; p=0.0001), despite high heterogeneity (I2=86%).
Only two46 48 reported on CNA, showing a trend towards
reduction with PERT (WMD: 0.61, −0.03 to 1.24; p=0.06).
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Figure 2 Daily lipase dose of pancreatic enzymes in the reported
studies. Black, non-EC microspheres; blue, minimicrospheres; cyan, EC
microspheres; EC, enteric-coated; grey, EC microtablets; USP, United
States Pharmacopoeia; white, non-EC microtablets; yellow, EC granules.
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Figure 3 The pooled clinical outcomes of pancreatic enzyme replacement therapy (PERT) versus baseline. (A) coefﬁcient of fat absorption (CFA),
(B) coefﬁcient of nitrogen absorption (CNA), (C) faecal fat excretion (FFE), (D) faecal nitrogen excretion (FNE) and (E) faecal weight.
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FFE,35 38 40 42 45 46 48 FNE38 46 48 and faecal
weight35 38 40 42 48 were consistently attenuated by PERT com-
pared with placebo (all p≤0.005), as was abdominal pain
(p=0.01),46 48 with a tendency to improved faecal consistency
but not stool frequency and ﬂatulence.45 46 48 Pooled data from
four studies38 45 46 48 found adverse event proﬁles similar with
PERTas placebo (p=0.9).
PERT versus PERT
Meta-analysis results of high versus low lipase dose regardless
of delivery system are shown in ﬁgure 5A and summarised in
table 3. Pooled CFA data from four studies32 33 40 47 showed a
higher CFA with high-dose PERT (≥60 000 USP units/day),
although not statistically signiﬁcant (89.2±2.0 vs 87.0±5.1;
WMD: 0.70, −0.27 to 1.67; p=0.16). Pooled FFE data from
these and one further study37 were similar, with moderate
heterogeneity for CFA (I2=69%) and FFE (I2=59%).
Meta-analysis of enteric-coated microspheres versus non-coated
microspheres is shown in ﬁgure 5B and summarised in table 3.
Pooled CFA data from three studies32–34 showed higher CFA
with enteric-coated microspheres, although not statistically sig-
niﬁcant (85.7±4.6 vs 75.4±10.0; WMD: 0.70, −0.27 to 1.67;
p=0.16). Similar ﬁndings were made from four studies32–34 36
reporting FFE with small sample sizes (n=18–55) and high
heterogeneity.
Subgroup analysis
Subgroup analyses of PERT versus baseline for studies of high-
quality, parallel multicentre, sample size ≥40 and in Western
populations did not change primary meta-analysis results or stat-
istical heterogeneity for CFA and FFE (table 4). Subgroup ana-
lyses of PERT versus placebo were similar, but heterogeneity
was signiﬁcantly reduced when sample size ≥40 for CFA
(I2=86% to 74%) and FFE (I2=85% to 67%).
Sensitivity analysis
Sensitivity analyses were performed as described in online
supplementary table S5. For PERT versus baseline, the results
and heterogeneity of CFA and FFE were not affected by diag-
nostic criteria for CP or EPI or by pancreatic surgery or by only
including studies with a proper run-in phase. Heterogeneity in
PERT versus placebo disappeared however for both CFA
(I2=0%; p=0.70) and FFE (I2=0%; p=0.92) when only includ-
ing CP deﬁned by imaging and/or histology.
Table 3 Results of meta-analyses for outcomes of interest
Effect estimate Heterogeneity
Outcomes of interest Studies, n Patients, n WMD/OR (95% CI) p Value I2 (%) p Value
PERT vs baseline PERT Baseline
CFA 11 228 229 2.28 (1.50 to 3.06) <0.00001 89 <0.00001
CNA 4 146 147 1.01 (0.39 to 1.62) 0.001 80 0.002
FFE 13 278 281 −1.66 (−12.19 to −1.13) <0.00001 84 <0.00001
FNE 4 93 94 −1.01 (−1.56 to −0.46) 0.0003 61 0.05
Faecal weight 6 107 111 −0.96 (−1.38 to −0.55) <0.00001 45 0.11
Faecal consistency: soft 2 58 58 0.47 (0.21 to 1.06) 0.07 63 0.10
Faecal consistency: formed/normal 2 58 58 2.26 (1.05 to 4.89) 0.04 54 0.14
Faecal frequency 2 49 49 −0.12 (−0.52 to 0.28) 0.55 0 0.87
Flatulence 2 58 58 0.36 (0.13 to 1.02) 0.06 0 0.67
Abdominal pain 2 58 58 0.53 (0.25 to 1.12) 0.10 0 0.62
PERT vs placebo PERT Placebo
CFA 7 124 114 1.67 (0.81 to 2.53) 0.0001 86 <0.00001
CNA 2 56 52 0.61 (−0.03 to 1.24) 0.06 62 0.11
FFE 7 124 114 −1.58 (−2.39 to −0.76) 0.0001 85 <0.00001
FNE 3 88 80 −0.54 (−0.85 to −0.22) 0.0007 40 0.19
Faecal weight 5 95 83 −0.92 (−1.56 to −0.28) 0.005 71 0.007
Faecal consistency: soft 2 58 55 0.42 (0.19 to 0.94) 0.03 0 0.89
Faecal consistency: formed/normal 2 58 55 1.20 (0.58 to 2.52) 0.62 87 0.006
Faecal frequency 3 70 69 −1.72 (−4.00 to 0.55) 0.14 96 <0.00001
Flatulence 2 58 55 1.20 (0.52 to 2.73) 0.67 88 0.004
Abdominal pain 2 58 55 0.37 (0.17 to 0.80) 0.01 0 0.85
Adverse event 4 104 96 1.05 (0.53 to 2.07) 0.9 0 0.83
PERT vs PERT High dose Low dose
CFA 4 88 90 0.70 (−0.27 to 1.67) 0.16 69 0.02
FFE 5 103 106 −0.43 (−1.05 to 0.19) 0.18 59 0.05
Enteric-coated vs non-coated Coated Non-coated
CFA 3 20 18 1.13 (−1.94 to 4.20) 0.47 91 <0.0001
FFE 4 55 53 −0.77 (−2.66 to 1.12) 0.42 89 <0.00001
CFA, coefficient of fat absorption; CNA, coefficient of nitrogen absorption; FFE, faecal fat excretion; FNE, faecal nitrogen excretion; PERT, pancreatic enzyme replacement therapy; WMD,
weighted mean difference.
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Figure 4 The pooled clinical outcomes of pancreatic enzyme replacement therapy (PERT) versus placebo. (A) coefﬁcient of fat absorption (CFA), (B)
coefﬁcient of nitrogen absorption (CNA), (C) faecal fat excretion (FFE), (D) faecal nitrogen excretion (FNE), (E) faecal weight and (F) adverse events.
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Meta-regression analysis
Covariates of study design (p=0.04) and daily lipase dose
(p=0.07) appeared to contribute to heterogeneity for FFE (see
online supplementary table S6); age, gender, study quality and
year of publication did not; limited data prevented assessment
of alcohol and DM.
Publication bias
There was no signiﬁcant evidence of publication bias for
either CFA (see online supplementary ﬁgure S1) or FFE (see
online supplementary ﬁgure S2) in PERT versus baseline,
PERT versus placebo, high dose versus low dose and enteric-
coated versus non-coated (Begg and Egger: p>0.10 for all
comparisons).
Extension studies
A 6-month, open-label trial49 (Creon 12000) extension of
Whitcomb’s study46 found PERT well tolerated, signiﬁcantly
improving serum nutritional parameters (retinol-binding
protein, prealbumin, albumin and cholesterol) and weight, redu-
cing faecal frequency, although no meaningful changes of QoL
scores were observed. A 51-week, open-label extension trial50
from Thorat’s study showed that Creon 40000 signiﬁcantly
improved laboratory nutritional parameters, fat and protein
absorption, GI symptoms and QoL, with a favourable safety and
tolerability proﬁle.
DISCUSSION
We found PERT to improve fat and protein absorption signiﬁ-
cantly in CP, demonstrated by marked, consistent increases in
CFA and CNA compared with baseline or placebo. Signiﬁcant
reductions in FFE, FNE, faecal weight and improvements in GI
symptoms were also observed across RCTs, unchanged by sub-
group, sensitivity and meta-regression analyses. Unlike in the
previous Cochrane review with meta-analysis of only two
studies,21 our meta-analysis of 14 RCTs demonstrates that PERT
is clearly indicated in CP for EPI. Even though long-term effects
on complications and mortality could not be determined, these
Figure 5 The pooled clinical outcomes of pancreatic enzyme replacement therapy (PERT) versus PERT. (A) coefﬁcient of fat absorption (CFA) and
faecal fat excretion (FFE) for high dose versus low dose and (B) CFA and FFE for enteric-coated versus non-coated.
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ﬁndings are similar to PERT for EPI in cystic ﬁbrosis,22 23
which, if extrapolated, suggest long-term beneﬁt. Although no
RCT was conducted over a period longer than 2 months, two
open-label extensions of up to 1 year demonstrated signiﬁcant
improvements in serum nutritional parameters, weight, GI
symptoms and QoL. Despite PERT not wholly normalising fat
absorption, driving the search for better enzymes and/or correc-
tion of other factors,9 the safety proﬁle of PERTwas comparable
to placebo, also favourable in the extension studies.
Healthy nutrient digestion and absorption requires complex
coordination of mechanical and enzymatic breakdown of food,
a ﬁnely tuned process depending on integration of multiple
upper GI functions including regulated, plentiful pancreatic exo-
crine and biliary secretion.9 Breakdown of fat relies on pancre-
atic lipase, which is highly susceptible to gastric acid; normally
pancreatic bicarbonate secretion ensures intra-duodenal pH of
5–6 for optimal enzymatic activity, also preventing bile acid pre-
cipitation. One study found that endogenous lipase activity has
to fall to <10% of normal before steatorrhoea occurs15 and
thus PERT should deliver ≥10% of normal lipase activity. The
amount of postprandial lipase secreted in a healthy adult is esti-
mated at between 9000 and 18 000 USP units/min for up to
4 hours.9 Therefore, delivery of at least 100 000 USP units per
meal (up to 400 000 USP units/120 000 international units in
severe EPI) is required to correct EPI in adult CP; although we
found a trend for higher doses to increase CFA, this increase
was not statistically signiﬁcant and did not fully correct malab-
sorption. Gastric acid inhibition can further enhance the efﬁcacy
of PERT;44 51 52 we found equal efﬁcacy of PERT at higher
doses alone compared with lower doses with gastric acid sup-
pression therapy, and an RCT not varying PERT between
groups found acid suppression therapy to signiﬁcantly improve
fat absorption.52 Further improvement may occur if PERT is
given during meals,43 corresponding with normal peak enzyme
secretion some 30 min after food, followed by an elevated
plateau.9 Future RCTs are required for deﬁnitive conclusions on
PERToptimisation.
EPI is frequent but variable in CP and typically progressive
over a number of years,1 3 5 8 contributing to long-term compli-
cations from malnutrition. Quantiﬁcation of CFA and/or FFE is
rarely undertaken routinely and clinical assessments of EPI are
inexact; EPI may be inferred from patient and imaging
characteristics, deﬁciencies in fat-soluble vitamins and osteopor-
osis, or identiﬁed by endoscopic pancreatic function testing
(normal peak pancreatic bicarbonate secretion >80 mEq/L).2
Lipid-soluble vitamins, retinol-binding protein, albumin and
prealbumin may be useful to monitor responses to PERT.49 50
Nevertheless, once the diagnosis of CP is established and since
some degree of EPI is likely,3 8 16–18 PERT is the treatment of
choice to reduce and/or minimise long-term malnutrition, unless
pancreatic secretion is demonstrated to be normal. Support for
this comes from a prospective, non-randomised, multicentre
1-year cohort study of 206 patients with EPI from CP already
on PERT and 88 with newly diagnosed EPI from CP newly pre-
scribed PERT.53 EPI was identiﬁed by maldigestion, diarrhoea/
steatorrhoea, weight loss, meteorism, dyspepsia, recurrent pain,
nausea and vomiting. PERT was associated with signiﬁcant
reductions in recurrent abdominal pain, GI symptoms and GI
Table 4 Results of subgroup analyses
Subgroups Studies, n
Patients, n Patients, n Effect estimate Heterogeneity
PERT Baseline or placebo WMD/OR (95% CI) p Value I2 (%) p Value
PERT vs baseline
CFA
High-quality studies 5 172 174 1.78 (0.85 to 2.70) 0.0002 92 <0.00001
Parallel designed 5 115 115 2.47 (1.42 to 3.52) <0.00001 89 <0.00001
Multicentre studies 4 140 140 2.13 (0.84 to 3.43) 0.001 94 <0.00001
Sample size ≥40 4 160 160 1.26 (0.51 to 2.00) 0.001 88 <0.00001
Western population 10 196 197 1.17 (0.94 to 1.40) <0.00001 90 <0.00001
FFE
High-quality studies 5 172 174 −1.44 (−2.18 to −0.71) <0.0001 88 <0.00001
Parallel designed 5 115 117 −1.66 (−2.19 to −1.13) <0.00001 85 <0.00001
Multicentre studies 4 140 142 −1.67 (−2.67 to −0.66) 0.001 91 <0.00001
Sample size ≥40 4 160 162 −1.06 (−1.61 to −0.50) 0.0002 80 0.002
Western population 12 246 247 −1.70 (−2.29 to −1.12) <0.00001 85 <0.00001
PERT vs placebo
CFA
High-quality studies 5 103 94 1.41 (0.51 to 2.31) 0.002 86 <0.00001
Parallel designed 5 107 97 2.03 (0.90 to 3.17) 0.0005 90 <0.00001
Multicentre studies 3 68 66 2.16 (0.85 to 3.48) 0.001 88 0.0003
Sample size ≥40 3 80 69 0.96 (0.28 to 1.64) 0.006 74 0.02
Western population 6 92 90 1.77 (0.68 to 2.86) 0.001 89 <0.00001
FFE
High-quality studies 5 103 94 −1.32 (−2.17 to −0.47) 0.002 85 <0.0001
Parallel designed 5 107 97 −1.90 (−2.97 to −0.82) 0.0005 90 <0.00001
Multicentre studies 3 68 66 −2.00 (−3.26 to −0.75) 0.002 87 0.0004
Sample size ≥40 3 80 69 −0.89 (−1.49 to −0.29) 0.004 67 0.05
Western population 6 92 90 −1.70 (−2.74 to −0.66) 0.001 88 <0.00001
CFA, coefficient of fat absorption; FFE, faecal fat excretion; PERT, pancreatic enzyme replacement therapy; WMD, weighted mean difference.
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QoL index (all p<0.001) in both cohorts, although uncertainty
remains as to how PERT reduces intestinal and/or pancreatic
pain.
Despite use of the more conservative random-effects model,
we found signiﬁcant heterogeneity between studies. Subgroup
analyses, however, did not alter estimates of the effect of PERT
versus baseline or placebo on CFA and FFE, nor estimates of
heterogeneity, although restriction of analysis to larger studies
reduced heterogeneity. Sensitivity analyses did not alter esti-
mates for CFA and FFE, but heterogeneity was abolished for
FFE in PERT versus placebo when CP was diagnosed by
imaging and/or histology criteria. The heterogeneity identiﬁed
highlights the need for greater international consensus on the
deﬁnition and diagnosis of CP.54
Access to medical expertise, compliance, diet and lifestyle is
heavily inﬂuenced by health inequalities.4 Proxy indicators,
notably alcohol usage and cigarette smoking, are themselves
independently associated with progression of CP and nutrient
deprivation.4 In our study, 76.4% of patients were male and
89.1% of patients had alcohol-associated CP, but none of the
RCTs reported measures of smoking, residence, socioeconomic
or employment status, diet or comorbidity. As genetic factors
and smoking have become increasingly recognised in CP pro-
gression,2 3 4 health inequalities should be addressed in future
studies of PERT to increase the applicability of ﬁndings to all
patients with CP.
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